Related Experiment Video

Updated: Aug 18, 2026

Development of Leishmania Species Strains with Constitutive Expression of eGFP
10:03

Development of Leishmania Species Strains with Constitutive Expression of eGFP

Published on: April 21, 2023

Second-generation vaccines against leishmaniasis

Rhea N Coler1, Steven G Reed

  • 1The Infectious Disease Research Institute, 1124 Columbia Street, Suite 600, Seattle, WA 98104, USA.

Trends in Parasitology
|April 20, 2005
PubMed

Insights

Developing effective vaccines against leishmaniasis is crucial due to drug resistance. Second-generation vaccines show promise for treating and preventing multiple Leishmania species (diseases).

Area of Science:

  • Parasitology
  • Immunology
  • Vaccinology

Background:

  • Leishmania parasites cause diverse human diseases, including cutaneous, visceral, mucosal, and diffuse cutaneous leishmaniasis.
  • Chemotherapy for leishmaniasis faces challenges due to drug resistance and toxicity, highlighting the need for alternative interventions.
  • Understanding immunopathogenesis and protective immunity is key to designing effective vaccines.

Purpose of the Study:

  • To review advances in second-generation vaccine development for leishmaniasis.
  • To discuss the potential of a single vaccine to protect against multiple Leishmania species and disease forms.
  • To highlight the characteristics of an ideal vaccine for treating and preventing leishmaniasis.

Main Methods:

  • Review of scientific literature on leishmaniasis vaccine research.
  • Analysis of identified and characterized vaccine candidate antigens.
  • Focus on second-generation vaccine strategies and their progress.

Main Results:

  • Several potential vaccine candidate antigens have been identified and characterized.
  • Second-generation vaccines are being developed to overcome limitations of earlier approaches.
  • Leishmania vaccines offer a unique opportunity for broad-spectrum protection against multiple species and disease manifestations.

Conclusions:

  • The development of effective and safe vaccines is a priority for combating leishmaniasis globally.
  • Second-generation vaccines represent a promising advancement in leishmaniasis prevention and treatment.
  • Further research into vaccine candidates and immunopathogenesis will be critical for successful vaccine implementation.

More Related Videos

In Vivo Infection with Leishmania amazonensis to Evaluate Parasite Virulence in Mice06:57

In Vivo Infection with Leishmania amazonensis to Evaluate Parasite Virulence in Mice

Published on: February 20, 2020

In vivo Imaging of Transgenic Leishmania Parasites in a Live Host09:53

In vivo Imaging of Transgenic Leishmania Parasites in a Live Host

Published on: July 27, 2010

Related Concept Videos

Antiprotozoal Agents01:21

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...
Leishmaniasis01:30

Leishmaniasis

Leishmaniasis is a protozoal disease caused by species of the genus Leishmania and transmitted through the bite of infected female sandflies. The parasite exists in two principal morphological forms during its life cycle. A sandfly acquires intracellular amastigotes from an infected reservoir host, such as a dog. Within the sandfly, these forms differentiate into motile, flagellated promastigotes. During a subsequent blood meal, promastigotes are injected into the human host, where they...
Anthelminthic Agents01:15

Anthelminthic Agents

Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...